Marker Therapeutics (MRKR) closed at $1.16 on October 20, 2026, down 3.3% from the previous close, on volume of 196,461 shares (30-day average 130,457).
Data as of October 20, 2026.
TipRanks (Tue, 20-Oct 7:40 AM ET)
Globe Newswire (Mon, 19-Oct 7:00 AM ET)
Globe Newswire (Tue, 22-Sep 8:00 AM ET)
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Marker Therapeutics trades on the NASDAQ stock market under the symbol MRKR.
As of October 21, 2026, MRKR stock price was flat at $1.16 with 128,452 million shares trading.
MRKR has a beta of 1.62, meaning it tends to be more sensitive to market movements. MRKR has a correlation of 0.06 to the broad based SPY ETF.
MRKR has a market cap of $19.34 million. This is considered a Sub-Micro Cap stock.
Last quarter Marker Therapeutics reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-665,600 and exceeded earnings estimates by $.10.
In the last 3 years, MRKR traded as high as $6.16 and as low as $.81.
The top ETF exchange traded funds that MRKR belongs to (by Net Assets): VTI, VXF.
MRKR has underperformed the market in the last year with a return of +12.6%, while the SPY ETF gained +16.1%. In the last 3 month period, MRKR fell short of the market, returning -9.4%, while SPY returned +4.2%. However, in the most recent 2 weeks MRKR has outperformed the stock market by returning +14.9%, while SPY returned -1.0%.
MRKR support price is $1.08 and resistance is $1.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRKR shares will trade within this expected range on the day.
